ISOFORMS OF HUMAN INTERLEUKIN-1 beta CONVERTING ENZYME AND METHODS OF USING THE SAME

Abstract: Substantially pure interleukin-1 converting enzyme isoforms are disclosed. Pharmaceutical compositions comprising one or more interleukin-1 converting enzyme isoforms are disclosed. Nucleic acid molecules that encode interleukin-1 converting enzyme isoforms, recombinant expression vectors that comprise a nucleic acid sequence that encodes an interleukin-1 converting enzyme isoform, and host cells that comprise recombinant expression vectors that comprise nucleic acid sequences that encode interleukin-1 converting enzyme isoforms are disclosed. Fragments of nucleic acid molecules with sequences encoding interleukin-1 converting enzyme isoform and oligonucleotide molecules that comprise a nucleotide sequence complimentary to fragment of a nucleotide sequence that encodes an interleukin-1 converting enzyme isoform are disclosed. Antibodies which bind to an epitope on interleukin-1 converting enzyme isoforms are disclosed. Methods of identifying inhibitors of ICE isoforms are disclosed.

Description: ISOFORMS OF HUMAN INTERLEUKIN- Iβ CONVERTING ENZYME AND METHODS OF USING THE SAME FIELD OF THE INVENTION The invention relates to the identification and cloning of four alternatively spliced mRNA that encode four isoforms of human interleukin- Iβ converting enzyme (ICE) with different apoptotic activities and to methods of making and using the same. BACKGROUND OF THE INVENTION Interleukin- Iβ converting enzyme, which is referred to herein as ICEα, is a cytoplasmic cysteine protease that cleaves inactive 31 kDa proIL-13 to generate the active 17.5 kDa proinflammatory cytokine IL-13 (Black, R.A., et al . (1989) FEBS Lett . 247, 386-390; and Kostura, M.J., et al. (1989) Proc . Na tl . Acad . Sci . USA 86, 5227-5231, which are each incorporated herein by reference) . ICEα is expressed in many tissues as an inactive proenzyme polypeptide of 404 amino acids (SEQ ID NO: 2) and a relative molecular mass (Mr) of 45 kDa (p45) (Cerretti, D.P., et al . (1992) Science 256, 97-100; and Thornberry, N.A. , et al . (1992) Na ture 356, 768-774) . Active ICEα is produced after proteolytic cleavage of the proenzyme p45 to generate two subunits of Mr 20 kDa and 10 kDa, known as p20 and plO subunits. Recent crystal structure analysis of active ICEc. demonstrated that the two subunits associate with each other to form a (p20) 2 / (PIO) 2 tetramer (Wilson, K.P., et al. (1994) Nature 370, 270-275) also referred to as a (p20/P10) 2 homodimer (Walker, Ν.P.C., et al . (1994) Cell 78, 343-352) . The structure of ICEα is unique and is not related to any known protein structures including those of other cysteine proteases. ICEα is also unusual in its substrate specificity. ICEα requires an Asp in the PI position and a small preferably hydrophobic residue in the PI' position (Sleath, P.R., et al . (1990) J. Biol . Chem. 265, 14526-14528; and Howard, A.D., et al . (1991) J. Im-nunol . 147, 2964-2969) . Only the serine protease granzyme B and its homologs have a similar requirement for Asp in the PI position. Sequence homology between ICEα and the Caenorhabdi tis elegans cell death gene product CED-3 suggests that mammalian ICEα or its homologs might be involved in apoptosis. The two proteins share an overall 28% sequence identity (Yuan, J. , et al . (1993) Cell 75, 641-652) . A 43% identity is observed when a region which contains the enzyme active site is compared. A significant homology between ICEα or CED-3, and a newly discovered mouse protein known as Nedd2 was also demonstrated in a recent study and the significance of this homology to CED- 3 was demonstrated when overexpression of ICEα or Nedd2 in fibroblasts resulted in apoptosis (Kumar, S., et al . (1994) Genes & Develpoment 8, 1613-1626; and Miura, M., et al . (1993) Cell 75, 653-660) . Expression of crmA, a poxvirus specific inhibitor of ICEα (Ray, C, e al. (1992) Cell 69, 597-604) was able to block ICEα apoptosis in fibroblasts and to protect ganglion neurons from apoptosis induced by nerve growth factor depletion (Gagliardini, V., et al . (1994) Science 263, 826- 828) . There is a need for compounds which inhibit activity of ICE isoforms. There is a need for kits and methods of identifying such compounds. There is a need for isolated ICE isoforms, and for compositions and methods of producing and isolating ICE isoforms. SUMMARY OF THE INVENTION The present invention relates to substantially pure interleukin-1 converting enzyme isoforms. The present invention relates to substantially pure interleukin-1 converting enzyme isoforms having the amino acid sequence of SEQ ID N0:4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO:10. The present invention relates to pharmaceutical compositions comprising one or more of the interleukin-1 converting enzyme isoforms. The present invention relates to nucleic acid molecules that encode interleukin-1 converting enzyme isoforms. The present invention relates to nucleic acid molecules encoding interleukin-1 converting enzyme isoforms that consist of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO: 7 or SEQ ID NO: 9. The present invention relates to recombinant expression vectors that comprise a nucleic acid sequence that encodes an interleukin-1 converting enzyme isoform. The present invention relates to host cells that comprise recombinant expression vectors that encode interleukin-1 converting enzyme isoforms. The present invention relates to fragments of nucleic acid molecules with sequences encoding interleukin-1 converting enzyme isoform that have at least 10 nucleotides. The present invention relates to oligonucleotide molecules that comprise a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. The present invention relates to isolated antibodies which bind to an epitope on SEQ ID NO:4 , SEQ ID NO: 6 , SEQ ID NO: 8 or SEQ ID NO: 10. The present invention relates to methods of identifying inhibitors of ICE isoforms. The methods comprise performing a control assay by contacting an ICE isoform with proIL-l? in the absence of a test compound under conditions in which the ICE isoform processes the proIL-l3, then performing a test assay by contacting an ICE isoform with proI -1^ in the presence of a test compound under conditions in which said ICE isoform processes the proIL-1 / S in the absence of said test compound, and then comparing the results of the two assays and determining whether the ICE isoform is active in the absence of test compound in the control assay and processes the proI -l / S but is not active in the presence of test compound in the test assay and does not processes the proIL-1/3. DETAILED DESCRIPTION OF THE INVENTION The present invention provides four novel human ICE mRNA isoforms which have been identified and characterized. The four isoforms of the ICE protein encoded by these mRNAs are designated ICE/3, ICEγ, ICEδ and ICEe. Together with ICEα, the four isoforms make up a family of five proteins in which three members, ICEα, ICEβ, and ICEγ, have similar function; ICEδ and ICEe function as inhibitors. The discovery of the four distinct isoforms provides the means to design and discover isoform specific inhibitors. According to the present invention, two of the four isoforms, ICEjS and ICEγ have a similar function as ICEα. These ICE isoforms may be used to screen compounds for isoform specific inhibitors. Inhibitors are useful as anti-inflammatory and anti-apoptotic agents. Kits are provided for screening compounds for ICE specific inhibitors. The nucleotide sequences of the isoforms disclosed herein allows for the production of pure proteins and the design of probes which specifically hybridize to nucleic acid molecules that encode ICE isoforms and antisense compounds to inhibit transcription of specific isoforms of ICE. Anti-ICE antibodies are provided which are specific for each of ICEβ, ICEγ and ICEδ as well as ICEe . Such antibodies are isoform specific inhibitors of ICE and may be used in methods of isolating pure ICE isoforms and methods of inhibiting ICE isoform activity. ICEe has been discovered to be an effective ICE inhibitor. According to this aspect of the invention, ICEe may be provided as a composition for inhibiting ICE in methods of inhibiting ICE. The four cDNAs that encode the isoforms ICE/3, ICEγ, ICEδ and ICEe result from one or more alternative splicing events involving exons 2 to 7 of the ICE gene (Cerretti, D.P., et al . (1994) Genomics 20, 468-473) . In ICE / 3 the deletion of exon 3 resulted from splicing of the DNA sequence between exon 2 and 4 using intron 2 splice donor and intron 3 splice acceptor (Tables I and II) . Similarly, the deletion of exon 7 in ICEδ resulted from splicing of the DNA sequence between exon 6 and 8 using intron 6 splice donor and intron 7 splice acceptor (Tables I and II) . On the other hand, the deletions within exon 2 to 7 in ICEγ, δ and e resulted from the use of an alternative splice donor located within the coding sequence of exon 2 (Tables I and II) . However, in ICEγ and δ intron 3 splice acceptor was used whereas in ICEe intron 7 splice acceptor was used (Tables I and II) . Three ICE mRNA species (2.5 kb, 1.9 kb and 0.5 kb) have been detected in THP-1 cell line and several other normal human tissues including peripheral blood monocytes, peripheral blood lymphocytes, peripheral blood neutrophils, resting and activated peripheral blood T-lymphocytes and placenta (Cerretti, D. P., et al . (1992) Science 256, 97-100) . The smallest 0.5 kb mRNA may be the ICEe isoform which is highly expressed in peripheral blood neutrophils and placenta. The present invention provides substantially purified ICE isoforms ICEβ, ICEγ, ICEδ and ICEe which have amino acid sequences consisting of: SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO:8 and SEQ ID NO: 10, respectively. ICE isoforms ICE3, ICEγ, ICEδ and ICEe can be isolated from natural sources, produced by recombinant DNA methods or synthesized by standard protein synthesis techniques. Antibodies which specifically bind to a particular ICE isoform may be used to purify the protein from natural sources using well known techniques and readily available starting materials. Such antibodies may also be used to purify the ICE isoform from material present when producing the protein by recombinant DNA methodology. The present invention relates to antibodies that bind to an epitope which is present on an ICE isoform selected from the group consisting of: ICE / β - SEQ ID N0:4, ICEγ - SEQ ID NO: 6 , ICEδ - SEQ ID NO: 8, and ICEe - SEQ ID NO: 10. As used herein, the term "antibody" is meant to refer to complete, intact antibodies, and Fab fragments and F(ab) 2 fragments thereof. Complete, intact antibodies include monoclonal antibodies such as murine monoclonal antibodies, chimeric antibodies and humanized antibodies. In some embodiments, the antibodies specifically bind to an epitope of only one of: ICEjβ - SEQ ID NO:4, ICEγ - SEQ ID NO:6, ICEδ - SEQ ID NO: 8, and ICEe - SEQ ID NO:10. Antibodies that bind to an epitope which is present on an ICE isoform are useful to isolate and purify the ICE isoform from both natural sources or recombinant expression systems using well known techniques such as affinity chromatography. Such antibodies are useful to detect the presence of such protein in a sample and to determine if cells are expressing the protein. The production of antibodies and the protein structures of complete, intact antibodies, Fab fragments and F(ab) 2 fragments and the organization of the genetic sequences that encode such molecules are well known and are described, for example, in Harlow, E. and D. Lane (1988) ANTIBODIES : A Labora tory Manual , Cold Spring Harbor Laboratory, Cold Spring Harbor, NY. which is incorporated herein by reference. Briefly, for example, the ICE isoform protein, or an immunogenic fragment thereof is injected into mice. The spleen of the mouse is removed, the spleen cells are isolated and fused with immortalized mouse cells. The hybrid cells, or hybridomas, are cultured and those cells which secrete antibodies are selected. The antibodies are analyzed and, if found to specifically bind to the ICE isoform, the hybridoma which produces them is cultured to produce a continuous supply of antibodies. Using standard techniques and readily available starting materials, a nucleic acid molecule that encodes each of the ICE isoform may be isolated from a cDNA library, using probes which are designed using the nucleotide sequence information disclosed in SEQ ID NO:3 , SEQ ID NO:5, SEQ ID NO: 7, or SEQ ID NO: 9. The present invention relates to an isolated nucleic acid molecule that comprises a nucleotide sequence that encodes an ICE isoform selected from the group consisting of ICEβ , ICEγ, ICEδ, and ICEe that comprises the amino acid sequence of SEQ ID N0:4, SEQ ID NO: 6, SEQ ID NO: 8 and SEQ ID NO:10, respectively. In some embodiments, the nucleic acid molecules consist of a nucleotide sequence that encodes ICE/3, ICEγ, ICEδ or ICEe. In some embodiments, the nucleic acid molecules comprise the nucleotide sequence that consists of the coding sequence in SEQ ID NO:3 , SEQ ID NO:5, SEQ ID NO: 7 or SEQ ID NO: 9. In some embodiments, the nucleic acid molecules consist of the nucleotide sequence set forth in SEQ ID NO: 3 , SEQ ID NO:5, SEQ ID NO: 7 and SEQ ID NO: 9. The isolated nucleic acid molecules of the invention are useful to prepare constructs and recombinant expression systems for preparing the ICE isoforms of the invention. A cDNA library may be generated by well known techniques. A cDNA clone which contains one of the nucleotide sequences set out is identified using probes that comprise at least a portion of the nucleotide sequence disclosed in SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. The probes have at least 16 nucleotides, preferably 24 nucleotides. The probes are used to screen the cDNA library using standard hybridization techniques. Alternatively, genomic clones may be isolated using genomic DNA from any human cell as a starting material. The present invention relates to isolated nucleic acid molecules that comprise a nucleotide sequence identical or complementary to a fragment of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9 which is at least 10 nucleotides. In some embodiments, the isolated nucleic acid molecules consist of a nucleotide sequence identical or complementary to a fragment of SEQ ID NO: 3 , SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9 which is at least 10 nucleotides. In some embodiments, the isolated nucleic acid molecules comprise or consist of a nucleotide sequence identical or complementary to a fragment of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9 which is 15-150 nucleotides. In some embodiments, the isolated nucleic acid molecules comprise or consist of a nucleotide sequence identical or complementary to a fragment of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO: 7 or SEQ ID NO: 9 which is 15-30 nucleotides. Isolated nucleic acid molecules that comprise or consist of a nucleotide sequence identical or complementary to a fragment of SEQ ID NO:3 , SEQ ID NO:5, SEQ ID NO: 7 or SEQ ID NO: 9 which is at least 10 nucleotides are useful as probes for identifying genes and cDNA sequence having SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO:7 or SEQ ID NO: 9, respectively, PCR primers for amplifying genes and cDNA having SEQ ID NO: 3 , SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9, respectively, and antisense molecules for inhibiting transcription and translation of genes and cDNA, respectively, which encode ICE isoforms having the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8 or SEQ ID NO: 10, respectively. The cDNA that encodes an ICE isoform may be used as a molecular marker in electrophoresis assays in which cDNA from a sample is separated on an electrophoresis gel and ICE isoform probes are used to identify bands which hybridize to such probes. Specifically, SEQ ID NO:3 or portions thereof, SEQ ID NO: 5 or portions thereof, SEQ ID NO:7 or portions thereof and SEQ ID NO: 9 or portions thereof, may be used as a molecular marker in electrophoresis assays in which cDNA from a sample is separated on an electrophoresis gel and ICE isoform specific probes are used to identify bands which hybridize to them, indicating that the band has a nucleotide sequence complementary to the sequence of the probes. The isolated nucleic acid molecule provided as a size marker will show up as a positive band which is known to hybridize to the probes and thus can be used as a reference point to the size of cDNA that encodes ICE / 3, ICEγ, ICEδ and ICEe, respectively. Electrophoresis gels useful in such an assay include standard polyacrylamide gels as described in Sambrook et al . , Mol ecular Cl oning a Labora tory Manual , Second Ed. Cold Spring Harbor Press (1989) which is incorporated herein by reference. The nucleotide sequence in SEQ ID NO: 3 , SEQ ID NO: 5, SEQ ID NO:7 and SEQ ID NO: 9, may be used to design probes, primers and complimentary molecules which specifically hybridize to the unique nucleotide sequences of ICE / S, ICEγ, ICEδ and ICEe, respectively. Probes, primers and complimentary molecules which specifically hybridize to nucleotide sequence that encodes ICE / S, ICEγ, ICEδ and ICEe may be designed routinely by those having ordinary skill in the art . The present invention also includes labelled oligonucleotides which are useful as probes for performing oligonucleotide hybridization methods to identify ICE/3, ICEγ, ICEδ and ICEe . Accordingly, the present invention includes probes that can be labelled and hybridized to unique nucleotide sequences of ICE/3, ICEγ, ICEδ and ICEe. The labelled probes of the present invention are labelled with radiolabelled nucleotides or are otherwise detectable by readily available nonradioactive detection systems. In some preferred embodiments, probes comprise oligonucleotides consisting of between 10 and 100 nucleotides. In some preferred, probes comprise oligonucleotides consisting of between 10 and 50 nucleotides. In some preferred, probes comprise oligonucleotides consisting of between 12 and 20 nucleotides. The probes preferably contain nucleotide sequence completely identical or complementary to a fragment of a unique nucleotide sequences of ICE / 3, ICEγ, ICEδ and ICEe. PCR technology is practiced routinely by those having ordinary skill in the art and its uses in diagnostics are well known and accepted. Methods for practicing PCR technology are disclosed in "PCR Protocols: A Guide to Methods and Applications", Innis, M.A., et al . Eds. Academic Press, Inc. San Diego, CA (1990) which is incorporated herein by reference. Applications of PCR technology are disclosed in "Polymerase Chain Reaction" Erlich, H.A., et al . , Eds. Cold Spring Harbor Press, Cold Spring Harbor, NY (1989) which is incorporated herein by reference. Some simple rules aid in the design of efficient primers. Typical primers are 18-28 nucleotides in length having 50% to 60% g+c composition. The entire primer is preferably complementary to the sequence it must hybridize to. Preferably, primers generate PCR products 100 basepairs to 2000 base pairs. However, it is possible to generate products of 50 base pairs to up to 10 kb and more. PCR technology allows for the rapid generation of multiple copies of nucleotide sequences by providing 5' and 3' primers that hybridize to sequences present in a nucleic acid molecule, and further providing free nucleotides and an enzyme which fills in the complementary bases to the nucleotide sequence between the primers with the free nucleotides to produce a complementary strand of DNA. The enzyme will fill in the complementary sequences adjacent to the primers. If both the 5' primer and 3' primer hybridize to nucleotide sequences on the complementary strands of the same fragment of nucleic acid, exponential amplification of a specific double- stranded product results. If only a single primer hybridizes to the nucleic acid molecule, linear amplification produces single-stranded products of variable length. One having ordinary skill in the art can isolate the nucleic acid molecule that encodes ICE / β, ICEγ, ICEδ and ICEe and insert it into an expression vector using standard techniques and readily available starting materials. The present invention relates to a recombinant expression vector that comprises a nucleotide sequence that encodes ICE/3, ICEγ, ICEδ or ICEe that comprises the amino acid sequence of SEQ ID NO:4, SEQ ID NO:6, SEQ ID NO: 8 and SEQ ID NO:10, respectively. As used herein, the term "recombinant expression vector" is meant to refer to a plasmid, phage, viral particle or other vector which, when introduced into an appropriate host, contains the necessary genetic elements to direct expression of the coding sequence that encodes the ICE isoforms of the invention. The coding sequence is operably linked to the necessary regulatory sequences. Expression vectors are well known and readily available. Examples of expression vectors include plasmids, phages, viral vectors and other nucleic acid molecules or nucleic acid molecule containing vehicles useful to transform host cells and facilitate expression of coding sequences. In some embodiments, the recombinant expression vector comprises the nucleotide sequence set forth in SEQ ID NO:3 , SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. The recombinant expression vectors of the invention are useful for transforming hosts to prepare recombinant expression systems for preparing the ICE isoforms of the invention. The present invention relates to a host cell that comprises the recombinant expression vector that includes a nucleotide sequence that encodes an ICE isoform that comprises SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. In some embodiments, the host cell comprises a recombinant expression vector that comprises SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. Host cells for use in well known recombinant expression systems for production of proteins are well known and readily available. Examples of host cells include bacteria cells such as E. coli , yeast cells such as S . cerevisiae, insect cells such as S . frugiperda , non-human mammalian tissue culture cells Chinese hamster ovary (CHO) cells and human tissue culture cells such as HeLa cells. The present invention relates to a transgenic non- human mammal that comprises the recombinant expression vector that comprises a nucleic acid sequence that encodes the collagen protein that comprises the amino acid sequence of SEQ ID NO:4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. Transgenic non-human mammals useful to produce recombinant proteins are well known as are the expression vectors necessary and the techniques for generating transgenic animals. Generally, the transgenic animal comprises a recombinant expression vector in which the nucleotide sequence that encodes an ICE isoform of the invention is operably linked to a mammary cell specific promoter whereby the coding sequence is only expressed in mammary cells and the recombinant protein so expressed is recovered from the animal's milk. In some embodiments, the coding sequence that encodes an ICE isoform is SEQ ID NO: 3 , SEQ ID NO:5, SEQ ID NO: 7 or SEQ ID NO: 9. In some embodiments, for example, one having ordinary skill in the art can, using well known techniques, insert such DNA molecules into a commercially available expression vector for use in well known expression systems. For example, the commercially available plasmid pSE420 (Invitrogen, San Diego, CA) may be used for production of collagen in E. coli . The commercially available plasmid pYES2 (Invitrogen, San Diego, CA) may, for example, be used for production in S. cerevisiae strains of yeast . The commercially available MAXBAC™ complete baculovirus expression system (Invitrogen, San Diego, CA) may, for example, be used for production in insect cells. The commercially available plasmid pcDNA I (Invitrogen, San Diego, CA) may, for example, be used for production in mammalian cells such as Chinese Hamster Ovary cells. One having ordinary skill in the art can use these commercial expression vectors and systems or others to produce an ICE isoform of the invention using routine techniques and readily available starting materials. {See e . g. , Sambrook et al . , Molecular Cloning a Labora tory Manual , Second Ed. Cold Spring Harbor Press (1989) which is incorporated herein by reference.) Thus, the desired proteins can be prepared in both prokaryotic and eukaryotic systems, resulting in a spectrum of processed forms of the protein. One having ordinary skill in the art may use other commercially available expression vectors and systems or produce vectors using well known methods and readily available starting materials. Expression systems containing the requisite control sequences, such as promoters and polyadenylation signals, and preferably enhancers, are readily available and known in the art for a variety of hosts . See e . g . , Sambrook et al . , Molecular Cloning a Labora tory Manual , Second Ed. Cold Spring Harbor Press (1989) . A wide variety of eukaryotic hosts are also now available for production of recombinant foreign proteins. As in bacteria, eukaryotic hosts may be transformed with expression systems which produce the desired protein directly, but more commonly signal sequences are provided to effect the secretion of the protein. Eukaryotic systems have the additional advantage that they are able to process introns which may occur in the genomic sequences encoding proteins of higher organisms. Eukaryotic systems also provide a variety of processing mechanisms which result in, for example, glycosylation, carboxy-terminal amidation, oxidation or derivatization of certain amino acid residues, conformational control, and so forth. Commonly used eukaryotic systems include, but is not limited to, yeast, fungal cells, insect cells, mammalian cells, avian cells, and cells of higher plants. Suitable promoters are available which are compatible and operable for use in each of these host types as well as are termination sequences and enhancers, e . g . the baculovirus polyhedron promoter. As above, promoters can be either constitutive or inducible. For example, in mammalian systems, the mouse metallothionein promoter can be induced by the addition of heavy metal ions. The particulars for the construction of expression systems suitable for desired hosts are known to those in the art. Briefly, for recombinant production of the protein, the DNA encoding the polypeptide is suitably ligated into the expression vector of choice. The DNA is operably linked to all regulatory elements which are necessary for expression of the DNA in the selected host. One having ordinary skill in the art can, using well known techniques, prepare expression vectors for recombinant production of the polypeptide. The expression vector including the DNA that encodes the ICE isoform is used to transform the compatible host which is then cultured and maintained under conditions wherein expression of the foreign DNA takes place. The protein of the present invention thus produced is recovered from the culture, either by lysing the cells or from the culture medium as appropriate and known to those in the art. One having ordinary skill in the art can, using well known techniques, isolate the ICE isoform that is produced using such expression systems. The methods of purifying ICE isoforms from natural sources using antibodies which specifically bind to the ICE isoform as described above, may be equally applied to purifying ICE isoforms produced by recombinant DNA methodology. Examples of genetic constructs include the ICE isoform coding sequence operably linked to a promoter that is functional in the cell line into which the constructs are transfected. Examples of constitutive promoters include promoters from cytomegalovirus or SV40. Examples of inducible promoters include mouse mammary leukemia virus or metallothionein promoters. Those having ordinary skill in the art can readily produce genetic constructs useful for transfecting with cells with DNA that encodes ICE isoform from readily available starting materials. Such gene constructs are useful for the production of the ICE isoform. In some embodiments of the invention, transgenic non- human animals are generated. The transgenic animals according to the invention contain SEQ ID NO:3, SEQ ID NO: 5, SEQ ID NO:7 or SEQ ID NO: 9 under the regulatory control of a mammary specific promoter. One having ordinary skill in the art using standard techniques, such as those taught in U.S. Patent No. 4,873,191 issued October 10, 1989 to Wagner and U.S. Patent No. 4,736,866 issued April 12, 1988 to Leder, both of which are incorporated herein by reference, can produce transgenic animals which produce the ICE isoform. Preferred animals are rodents, particularly goats, rats and mice. In addition to producing these proteins by recombinant techniques, automated peptide synthesizers may also be employed to produce ICE isoforms of the invention. Such techniques are well known to those having ordinary skill in the art and are useful if derivatives which have substitutions not provided for in DNA-encoded protein production. ICEe/p20 heterodimers are inactive. ICE activity may be regulated this way, i.e. at the level of formation of ICE heterodimer. The ICEe cDNA codes for a protein which corresponds to the plO subunit of ICEα except for the first 19 amino acids, which are derived from exon 2 in ICEe, and from exon 7 in the plO subunit. ICEe, like the plO subunit, can form a heterodimer with the p20 subunit. The crystal structure of ICEα complexed to a tetrapeptide aldehyde inhibitor suggests that the side chains of plO residues Val338 to Pro343 interact with the inhibitor, except for Ser339 (Cerretti, D.P., et al . (1992) Science 256, 97-100) . Although all these residues are present in ICEe, the ICEe/p20 heterodimer is inactive. This could be attributed to the fact that active ICE exists as a (p20) 2 / (PIO) 2 tetramer in which the participation of plO residues 318-322 in the formation of this tetrameric complex is essential (Wilson, K.P., e al. (1994) Na ture 370, 270-275) . Because 4 of these residues are substituted in ICEe, this may prevent the formation of a (p20) 2 / (ICEe) 2 tetramer. The biological significance of the expression of an alternatively spliced ICEe isoform is realized from its ability to modulate ICE activity. ICEe might compete with plO for binding to p20 in vivo . Overexpression of ICEe in Sf9 cells resulted in a delay of apoptosis in a fashion similar to or even better than BCL2 expression. Insect Sf9 cells apparently express an ICE-like protein which might be involved in insect cell apoptosis. Support for the existence of an ICE-like molecule in Sf9 cells was obtained from our overexpression studies of pro-IL-1/3. Overexpression of pro-IL-13 in Sf9 cells resulted in its cleavage to the 17.5 kDa active IL-1/3 cytokine. Three ICE mRΝA species (2.5 kb, 1. kb and 0.5 kb) have been detected in THP-1 cell line and several other normal human tissues including peripheral blood monocytes, peripheral blood lymphocytes, peripheral blood neutrophils, resting and activated peripheral blood T-lymphocytes and placenta. The smallest 0.5 kb mRΝA may be the ICEe isoform. ICEe transcript is highly expressed in peripheral blood neutrophils and placenta. The significance of this high level of expression is not yet established. By acting as a dominant inhibitor, ICEe may inhibit ICE activity thus indirect regulating apoptosis in these tissues. Accordingly, ICEe may be used as a pharmaceutical to inhibit ICE activity which is involved in both inflammation and apoptosis. Inflammatory diseases include rheumatoid arthritis and Crohn's diseases. Diseases characterized by apoptosis include HIV infection and Alzheimer's disease. Those having ordinary skill in the art can readily identify individuals who are suspected of suffering from such diseases, conditions and disorders using standard diagnostic techniques. Pharmaceutical compositions according to the invention comprise a pharmaceutically acceptable carrier in combination with an ICE isoform, particularly, ICEδ and ICEe . ICEδ and ICEe function as inhibitors. Pharmaceutical formulations for are well known and pharmaceutical compositions comprising ICEe and ICEδ may be routinely formulated by one having ordinary skill in the art. Suitable pharmaceutical carriers are described in Remington ' s Pharmaceutical Sciences , A. Osol, a standard reference text in this field, which is incorporated herein by reference. The present invention relates to an injectable pharmaceutical composition that comprises a pharmaceutically acceptable carrier and an ICE isoform, particularly, ICEe or ICEδ. Some embodiments of the invention relate to injectable pharmaceutical compositions that comprise a pharmaceutically acceptable carrier and amino acid sequence SEQ ID NO: 8 or SEQ ID NO: 10. The ICE isoform is preferably sterile and combined with a sterile pharmaceutical carrier. In some embodiments, for example, ICEe or ICEδ can be formulated as a solution, suspension, emulsion or lyophilized powder in association with a pharmaceutically acceptable vehicle. Examples of such vehicles are water, saline, Ringer's solution, dextrose solution, and 5% human serum albumin. Liposomes and nonaqueous vehicles such as fixed oils may also be used. The vehicle or lyophilized powder may contain additives that maintain isotonicity (e.g., sodium chloride, mannitol) and chemical stability (e.g., buffers and preservatives) . The formulation is sterilized by commonly used techniques . An injectable composition may comprise ICEe and/or ICEδ in a diluting agent such as, for example, sterile water, electrolytes/dextrose, fatty oils of vegetable origin, fatty esters, or polyols, such as propylene glycol and polyethylene glycol. The injectable must be sterile and free of pyrogens . According to one aspect of the invention, compounds may be screened to identify ICE inhibitors. Since ICE converts IL-ljβ from an inactive to an active form and IL-1/3 is associated with inflammation, inhibitors are useful as anti- inflammatory agents. Furthermore, it has been discovered and reported herein that ICE activity is associated with apoptosis. Accordingly, inhibitors of ICE are useful as anti-apoptotic agents . To screen compounds according to the methods of the present invention, ICE / S or ICEγ is separately combined with proIL-1/3 in the presence or absence of a test compound. Under assay conditions, the proIL-1/3 will be processed into active IL-1 in the absence of test compound. Those having ordinary skill in the art can readily detect whether or not proIL-1/3 has been processed. If proIL-1 / S is not processed in the presence of the test compound but is processed under the negative control condition in which the test compound is absent, the test compound is an inhibitor of that ICE isoform. Antibodies which inhibit the ICE isoform' s activity are useful as inhibitors and, therefore as positive controls in the assay. In some embodiments, ICEα together with ICE / 3 and ICEγ are each tested to identify ICE inhibitors and to determine if any inhibitors are isoform specific. Kits are included which comprise containers with reagents necessary to screen test compounds. Such kits include one or more ICE isoforms, including, optionally ICEα together with a substrate such as IL-l / S and a means to distinguish processed substrate from uncleaved substrate. Directions for performing the assay are also included in the kit. The means for distinguishing processed substrate from uncleaved substrate include, for example, antibodies which bind to processed substrate but not uncleaved substrate, antibodies which bind to uncleaved substrate but not processed substrate, and liberation assay reagents in labelled uncleaved substrate is bound to solid phase and upon processing of the substrate by the enzyme the label is liberated from the solid phase at which time it is either detected as unbound or its absence is detected from the bound material . Those of ordinary skill in the art can readily design kits to practice the assays of the invention and measure the capacity of test compounds to inhibit ICE isoform activity. Inhibitors are useful as an i- inflammatory and anti-apoptotic agents. According to another aspect of the invention, ICEδ and ICEe can be used in gene therapy to inhibit ICE activity in several degenerative diseases. By introducing into cells the cDNA that encodes either ICEδ or ICEe in an expressible form, ICEδ or ICEe will be expressed and inhibit ICE activity. Example 1 MATERIALS AND METHODS Cloning of ICE Isoforms. The cDNAs for individual ICE isoforms were cloned by a combination of reverse transcription and polymerase chain reaction techniques (RT-PCR) . Reverse transcription was performed on poly A+ RNA from the human T-lymphocyte cell line Jurkat or total RNA from the human monocyte cell line THP-1 using a synthetic primer (ICE-RT) derived from the 3' untranslated sequence of human ICE and MuMLV reverse transcriptase. The reverse transcription products were then used as templates for PCR using two nested ICE specific primers ICE1 and ICE2. Primer sequences were as follows: ICE-RT, CAGAACGATCTCTTCAC SEQ ID NO: 11; ICE1, ATGGCCGACAAGGTCCTG SEQ ID NO:12; and ICE2, CCTGCCCGCAGACATTCA SEQ ID NO:13. The amplified DNA was blunt-ended with T4 DNA polymerase, phosphorylated with T4 polynucleotide kinase and then fractionated on low melting point agarose gels. Several DNA fragments ranging in size from 0.3-1.3 Kb were observed after staining the gel with ethidium bromide. After confirming that all these DNA fragments contain ICE sequences by Southern blot analysis with an ICE specific probe, they were excised from the gel and cloned into a Sma I cut pbluescript II KS+ vector (Stratagene) . The cloned cDNAs were then sequenced with T3 and T7 sequencing primers and other ICE specific primers. The largest clone corresponding to the published ICE sequence was designated as KS-ICEα. The other ICE clones were designated as KS-ICE/3, KS-ICEγ, KS-ICEδ and KS-ICEe, based on decreasing size. Construction of Plasmids, Transfer Vectors and Recombinant Baculoviruses. As outlined above, cDNAs for each individual ICE isoforms were cloned in the Sma I site of pbluescript II KS+ plasmid vector under the T7 promoter. The cDNAs for the p20 and plO subunits were obtained by PCR using synthetic primers (ICEl and p20TAA for p20; plOATG and ICE2 for plO) and KS-ICEγ as a template. The sequence of the p20TAA primer is GGTTTCCAGAAACTCCTACTTAATC SEQ ID NO: 14 and the plOATG primer is ATGGCTATTAAGAAAGCCCACATA SEQ ID NO: 15. The amplified DNA fragments were blunt-ended, phosphorylated and then cloned in the Sma I site of pbluescript II KS+ vector under the T7 promoter and designated as KS-plO and KS-p20. The cDNA fragments corresponding to ICEα, β , γ, δ, e, p20 and plO were excised from their corresponding bluescript vectors with Bam HI and Eco RI restriction enzymes and subcloned into a Bam HI/Eco RI cut pVL1393 to generate the corresponding recombinant transfer vectors. These recombinant transfer vectors were then used to generate recombinant baculoviruses. In vi tro Transcription and Translation. The five KS-ICE or KS-plO vectors were linearized with Eco RI and then used as templates for T7 RNA polymerase. The in vi tro synthesized mRNA was precipitated by ethanol, dried and dissolved in TE buffer (10 mM Tris, pH 8.0, 1 mM EDTA) . In vi tro translation was performed in rabbit reticulocyte lysate in the presence of 80 μCi/ml of 35 S methionine and 200 μg/ml in vi tro transcribed mRNA. The translation products were then analyzed by SDS-polyacrylamide gel electrophoresis and autoradiography. Expression of GST-p20 Fusion Protein in Bacteria. The p20 cDNA was subcloned in frame into the Bam HI site of the bacterial expression vector pGEX-5X-3 (Pharmacia) . The p20 cDNA was obtained by PCR using synthetic primers p20GEX and p20TAA and KS-ICEγ as a template. The sequence of p20GEX primer is GGGATCCTGAACCCAGCTATGCCCACATCC SEQ ID NO: 16. The amplified DNA fragment was blunt-ended, phosphorylated and then cloned in the Sma I site of pbluescript II KS+ vector under the T7 promoter. The cDNA fragment was then excised from the bluescript vectors with Bam HI and then subcloned in a Bam HI cut pGEX-5X-3. The expression plasmid PGEX-p20 was introduced into E. col i DH5α and protein expression was induced with IPTG. Analysis of p20 Interaction with plO and ICEe . Exponentially growing bacteria carrying the expression plasmid PGEX-p20 was induced with IPTG for 3 h and then lysed by sonication. The recombinant GST-p20 present in the bacterial lysate was adsorbed to glutathione-sepharose resin for 10 min at room temperature and then washed three times with PBS. The immobilized p20 fusion protein was incubated with reticulocyte lysates containing 35 S-labeled plO or ICEe for 1 h at 30°C and then washed five times with PBS containing 0.1% Triton X-100. Laemmli sample buffer was then added to the resin and the eluted proteins were analyzed on a 5-20% SDS- polyacrylamide gradient gel and visualized by autoradiography. RESULTS Cloning of four novel ICE isoforms. Employing RT-PCR to analyze the expression of ICE mRNA in the human Jurkat T-lymphocyte cell line, several DNA products of 1248, 1185, 969, 825 and 300 bp were detected by ethidium bromide staining. The two largest PCR products were the most abundant. All five products were detected by Southern blot hybridization using the full length ICE cDNA as a probe. This pattern of RT-PCR products was also observed using total RNA from the human acute monocytic leukemia cell line THIP-1. Subsequently, the two largest PCR products (1185 and 1248 bp) were cloned from Jurkat mRNA and the three smaller less abundant products (300, 825 and 969 bp) which represent 10-15% of the larger products were cloned from THP-1 mRNA. All cloned PCR products were then sequenced. The largest form (1248 bp) corresponds to the sequence of the full length ICE as reported previously and was designated as ICEα. Intriguingly, sequence analysis of the four smaller PCR products revealed that these forms were generated by independent alternative splicing events of the parental ICE mRNA transcript. Table I lists the deletion sizes in the isoforms and the amino acid interrupted due to the splice. Table II lists the splice donor and acceptor sequences of the human ICE gene that are utilized to generate the four ICE isoforms. All the splice junction sequences within the splice donor and acceptor sites conform to the consensus GT/AG rule . The 1185 bp cDNA, designated as ICE/3 lacks the entire exon 3 of the ICE gene (bp 275 to 338; a.a 92-112) . The 969 bp cDNA, designated as ICEγ, lacks most of exon 2 and the entire exon 3 (bp 59 to 338; a.a 20-112) . The 825 bp cDNA, designated as ICEδ is similar to ICEγ but also lacks the entire exon 7 (bp 863 to 1006; a.a 288-335) . The smallest 300 bp cDNA, designated as ICEe lacks most of exon 2 and exons 3 to 7 (bp 59 to 1006; a.a 20-335) . All these alternatively spliced ICE isoforms maintained an open reading frame which gave rise to different translation products. ICE proenzyme (ICEα here) requires proteolytic cleavage to generate p20 and plO subunits for enzymatic activation. It is not yet clear whether ICE activation occurs via an intramolecular autoprocessing mechanism or requires limited proteolysis by an unknown protease. However, it has been shown that active ICE heterodimer can cleave reticulocyte lysate translated proICE to generate the p20 and plO subunits. Because ICE isoforms β , γ and δ contain the active site Cys285 but lack part or most of the 119 N-terminal propeptide it was interesting to determine whether these isoforms possess autoprocessing activity. ICE isoforms α, β , γ and δ were in vi tro transcribed and translated in rabbit reticulocyte lysates . Translation of ICE mRNA isoforms gave rise to 30-48 kDa translation products. A major 34 kDa product in ICEα and ICE/3 translation reactions was also detected. This p34 product is similar in size to the ICEγ translation product and could be a processed ICEα and β . However, all these products were stable for 24 h in reticulocyte lysates at room temperature. No decrease in the intensity of the 30-48 kDa translation products or appearance of a p20 species was observed after this prolonged incubation. In addition, incubation of ICEα with ICEγ or ICEδ, or incubation of ICEγ with ICEδ for 24 h at room temperature did not result in processing of these isoforms to the p20 and plO subunits. The stability of the ICE isoforms suggests that ICE isoforms do not possess autocatalytic activity under these in vi tro conditions. Determination of the apoptotic activity of ICE isoforms. To determine the ability of the individual ICE isoforms to induce apoptosis, each ICE isoform was overexpressed in Spodoptera frugiperda (Sf9) cells with the baculovirus system. The viability of infected cells was determined at various times postinfection. The viability of Sf9 cells infected with the recombinant ICEα baculovirus decreased sharply 24-48 h postinfection. Similar effects were also observed with ICE/3 and ICEγ. In contrast, cells infected with the wild type virus, ICEδ, ICEe, or BCL2 baculoviruses showed very little decrease in viability during this period. The decrease in viability of cells infected with the recombinant ICEα, β and γ baculoviruses was due to induction of apoptosis when the recombinant ICE proteins started to rise 24-48 h postinfection. This period is the time at which proteins under the polyhedrin promoter are induced. During this period, cells expressing ICEα, β or γ showed characteristic signs of apoptosis including cytoplasmic membrane blebbing, nuclear condensation and internucleosomal DNA cleavage. These apoptotic signs were not observed in Sf9 cells infected with ICEδ or e, baculoviruses or with the wild type or BCL2 baculoviruses (Alne ri, E. S., et al . (1992) Proc. Na tl . Acad . Sci . USA 89, 7295-7299) . In fact, it was surprising to discover that expression of ICEe and to a lesser degree ICEδ conferred some protection and delayed the apoptotic response to baculovirus infection. In this experiment, cells infected with ICEe baculovirus showed a lesser decrease in viability compared to cells infected with the wild type virus. This protective effect was similar to that observed with the expression of BCL2 in these cells. Coexpression of ICEα with BCL2 or ICEe resulted in a slight delay in the onset of apoptosis, but was not protective. Because of the lethality of ICEα, a significantly lower expression of BCL2 or ICEe was detected in this coexpression experiment . Because ICEe is homologous to the plO subunit of active ICE, its coexpression with the p20 subunit was tested to determine whether could generate an active ICE heterodimer. The results of these experiments showed that expression of either the plO, p20 or ICEe in Sf9 cells does not cause apoptosis. On the other hand, coexpression of the plO and p20 subunits resulted in apoptosis within the same time frame as did ICEα. In contrast, coexpression of ICEe and p20 does not cause apoptosis in Sf9 cells. These results suggest that the first 19 amino acids of the plO subunit are essential for ICE activity. Substitution of these amino acids as in ICEe may result in loss of activity. Determination of the ability of ICEe to interact with p20. To determine whether ICEe can interact with p20, ICEe was in vi tro transcribed and then translated in reticulocyte lysate in the presence of 35 S methionine. The labeled ICEe was then incubated with a GST-p20 fusion protein expressed in bacteria and immobilized on glutathione-sepharose resin. The plO subunit was also labeled in reticulocyte lysate with 35 S and used as a control. Both plO and ICEe were able to interact with the GST-p20 fusion protein. A small amount of plO and ICEe were bound nonspecifically to free glutathione-sepharose resin. These results suggest that ICEe can form a heterodimer with p20 and may regulate its activity in vivo by forming an inactive complex. Table I Dele tion in ICE isoforms . The size of deletions refer to the number of base pairs deleted in the respective splice variants. Also listed is the amino acid interrupted by the splice . Size of deletion Isoform (bp) Amino acid interrupted β 63 Asp92 γ 179 Gly20 δ 179 Gly20 δ 143 Asp288 e 957 Gly20 Table II Splice junction sequences in ICE isoforms. The intron sequences at the splice junctions are represented in lowercase. The exon sequences at the splice junctions and the exon 2 sequence used as the internal splice donor in ICE γ, δ and e are represented in uppercase. Isoform Donor Acceptor 0 GCA G gtaagggtca....tctcttgcag CT CCT (SEQ ID NO: 17) γ GAA G GTACAATAAA....tctcttgcag CT CCT (SEQ ID NO:18) δ GAA G GTACAATAAA....tctcttgcag CT CCT (SEQ ID NO:19) δ GGT G gtgagtgctg....ttatccatag AT AAT (SEQ ID NO:20) e GAA G GTACAATAAA....ttatccatag AT AAT (SEQ ID NO:21) SEQUENCE LISTING (1) GENERAL INFORMATION: (i) APPLICANT: Litwac , Gerald Alnemri, Emad S. Fernandez-Alnemri, Teresa (ii) TITLE OF INVENTION: ISOFORMS OF HUMAN INTERLEUKIN-1BETA CONVERTING ENZYME AND METHODS OF USING THE SAME (iii) NUMBER OF SEQUENCES: 21 (iv) CORRESPONDENCE ADDRESS: (A) ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & Norris (B) STREET: One Liberty Place, 46th floor (C) CITY: Philadelphia (D) STATE: PA (E) COUNTRY: USA (F) ZIP: 19103 (v) COMPUTER READABLE FORM: (A) MEDIUM TYPE: Floppy disk (B) COMPUTER: IBM PC compatible (C) OPERATING SYSTEM: PC-DOS/MS-DOS (D) SOFTWARE: Wordperfect 5.1 (vi) CURRENT APPLICATION DATA: (A) APPLICATION NUMBER: (B) FILING DATE: (C) CLASSIFICATION: (vii) PRIOR APPLICATION DATA: (A) APPLICATION NUMBER: US 08/391,916 (B) FILING DATE: 21-FEB-1995 (C) CLASSIFICATION: (viii) ATTORNE /AGENT INFORMATION: (A) NAME: DeLuca, Mark (B) REGISTRATION NUMBER: 33,229 (C) REFERENCE/DOCKET NUMBER: TJU-1795 (ix) TELECOMMUNICATION INFORMATION: (A) TELEPHONE: (215) 568-3100 (B) TELEFAX: (215) 568-3439 (2) INFORMATION FOR SEQ ID NO: 1 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1248 base pairs (B) TYPE: nucleic acid (C) ΞTRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE : (A) NAME/KEY: CDS (B) LOCATION: 1..1212 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1 : ATG GCC GAC AAG GTC CTG AAG GAG AAG AGA AAG CTG TTT ATC CGT TCC 48 Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe lie Arg Ser 1 5 10 15 ATG GGT GAA GGT ACA ATA AAT GGC TTA CTG GAT GAA TTA TTA CAG ACA 96 Met Gly Glu Gly Thr lie Asn Gly Leu Leu Asp Glu Leu Leu Gin Thr 20 25 30 AGG GTG CTG AAC AAG GAA GAG ATG GAG AAA GTA AAA CGT GAA AAT GCT 144 Arg Val Leu Asn Lys Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala 35 40 45 ACA GTT ATG GAT AAG ACC CGA GCT TTG ATT GAC TCC GTT ATT CCG AAA 192 Thr Val Met Asp Lys Thr Arg Ala Leu lie Asp Ser Val lie Pro Lys 50 55 60 GGG GCA CAG GCA TGC CAA ATT TGC ATC ACA TAC ATT TGT GAA GAA GAC 240 Gly Ala Gin Ala Cys Gin lie Cys lie Thr Tyr lie Cys Glu Glu Asp 65 70 75 80 AGT TAC CTG GCA GGG ACG CTG GGA CTC TCA GCA GAT CAA ACA TCT GGA 288 Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Asp Gin Thr Ser Gly 85 90 95 AAT TAC CTT AAT ATG CAA GAC TCT CAA GGA GTA CTT TCT TCC TTT CCA 336 Asn Tyr Leu Asn Met Gin Asp Ser Gin Gly Val Leu Ser Ser Phe Pro 100 105 110 GCT CCT CAG GCA GTG CAG GAC AAC CCA GCT ATG CCC ACA TCC TCA GGC 384 Ala Pro Gin Ala Val Gin Asp Asn Pro Ala Met Pro Thr Ser Ser Gly 115 120 125 TCA GAA GGG AAT GTC AAG CTT TGC TCC CTA GAA GAA GCT CAA AGG ATA 432 Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala Gin Arg lie 130 135 140 TGG AAA CAA AAG TCG GCA GAG ATT TAT CCA ATA ATG GAC AAG TCA AGC 480 Trp Lys Gin Lys Ser Ala Glu lie Tyr Pro lie Met Asp Lys Ser Ser 145 150 155 160 CGC ACA CGT CTT GCT CTC ATT ATC TGC AAT GAA GAA TTT GAC AGT ATT 528 Arg Thr Arg Leu Ala Leu lie lie Cys Asn Glu Glu Phe Asp Ser lie 165 170 175 CCT AGA AGA ACT GGA GCT GAG GTT GAC ATC ACA GGC ATG ACA ATG CTG 576 Pro Arg Arg Thr Gly Ala Glu Val Asp lie Thr Gly Met Thr Met Leu 180 185 190 CTA CAA AAT CTG GGG TAC AGC GTA GAT GTG AAA AAA AAT CTC ACT GCT 624 Leu Gin Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn Leu Thr Ala 195 200 205 TCG GAC ATG ACT ACA GAG CTG GAG GCA TTT GCA CAC CGC CCA GAG CAC 672 Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg Pro Glu His 210 215 220 AAG ACC TCT GAC AGC ACG TTC CTG GTG TTC ATG TCT CAT GGT ATT CGG 720 Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His Gly lie Arg 225 230 235 240 GAA GGC ATT TGT GGG AAG AAA CAC TCT GAG CAA GTC CCA GAT ATA CTA 768 Glu Gly lie Cys Gly Lys Lys His Ser Glu Gin Val Pro Asp lie Leu 245 250 255 CAA CTC AAT GCA ATC TTT AAC ATG TTG AAT ACC AAG AAC TGC CCA AGT 816 Gin Leu Asn Ala lie Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser 260 265 270 TTG AAG GAC AAA CCG AAG GTG ATC ATC ATC CAG GCC TGC CGT GGT GAC 864 Leu Lys Asp Lys Pro Lys Val lie lie lie Gin Ala Cys Arg Gly Asp 275 280 285 AGC CCT GGT GTG GTG TGG TTT AAA GAT TCA GTA GGA GTT TCT GGA AAC 912 Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly Val Ser Gly Asn 290 295 300 CTA TCT TTA CCA ACT ACA GAA GAG TTT GAG GAT GAT GCT ATT AAG AAA 960 Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala lie Lys Lys 305 310 315 320 GCC CAC ATA GAG AAG GAT TTT ATC GCT TTC TGC TCT TCC ACA CCA GAT 1008 Ala His lie Glu Lys Asp Phe lie Ala Phe Cys Ser Ser Thr Pro Asp 325 330 335 AAT GTT TCT TGG AGA CAT CCC ACA ATG GGC TCT GTT TTT ATT GGA AGA 1056 Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe lie Gly Arg 340 345 350 CTC ATT GAA CAT ATG CAA GAA TAT GCC TGT TCC TGT GAT GTG GAG GAA 1104 Leu lie Glu His Met Gin Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu 355 360 365 ATT TTC CGC AAG GTT CGA TTT TCA TTT GAG CAG CCA GAT GGT AGA GCG 1152 lie Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro Asp Gly Arg Ala 370 375 380 CAG ATG CCC ACC ACT GAA AGA GTG ACT TTG ACA AGA TGT TTC TAC CTC 1200 Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu 385 390 395 400 TTC CCA GGA CAT TAAAATAAGG AAACTGTATG AATGTCTGCG GGCAGG 1248 Phe Pro Gly His (2) INFORMATION FOR SEQ ID NO:2 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 404 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:2 : Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe lie Arg Ser 1 5 10 15 Met Gly Glu Gly Thr lie Asn Gly Leu Leu Asp Glu Leu Leu Gin Thr 20 25 30 Arg Val Leu Asn Lys Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala 35 40 45 Thr Val Met Asp Lys Thr Arg Ala Leu lie Asp Ser Val lie Pro Lys 50 55 60 Gly Ala Gin Ala Cys Gin lie Cys lie Thr Tyr lie Cys Glu Glu Asp 65 70 75 80 Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Asp Gin Thr Ser Gly 85 90 95 Asn Tyr Leu Asn Met Gin Asp Ser Gin Gly Val Leu Ser Ser Phe Pro 100 105 110 Ala Pro Gin Ala Val Gin Asp Asn Pro Ala Met Pro Thr Ser Ser Gly 115 120 125 Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala Gin Arg lie 130 135 140 Trp Lys Gin Lys Ser Ala Glu lie Tyr Pro lie Met Asp Lys Ser Ser 145 150 155 160 Arg Thr Arg Leu Ala Leu lie He Cys Asn Glu Glu Phe Asp Ser He 165 170 175 Pro Arg Arg Thr Gly Ala Glu Val Asp He Thr Gly Met Thr Met Leu 180 185 190 Leu Gin Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn Leu Thr Ala 195 200 205 Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg Pro Glu His 210 215 220 Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His Gly He Arg 225 230 235 240 Glu Gly He Cys Gly Lys Lys His Ser Glu Gin Val Pro Asp He Leu 245 250 255 Gin Leu Asn Ala He Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser 260 265 270 Leu Lys Asp Lys Pro Lys Val He He He Gin Ala Cys Arg Gly Asp 275 280 285 Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly Val Ser Gly Asn 290 295 300 Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala He Lys Lys 305 310 315 320 Ala His He Glu Lys Asp Phe He Ala Phe Cys Ser Ser Thr Pro Asp 325 330 335 Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe He Gly Arg 340 345 350 Leu He Glu His Met Gin Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu 355 360 365 He Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro Asp Gly Arg Ala 370 375 380 Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu 385 390 395 400 Phe Pro Gly His (2) INFORMATION FOR SEQ ID NO: 3 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 1185 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS : double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..1149 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3 : ATG GCC GAC AAG GTC CTG AAG GAG AAG AGA AAG CTG TTT ATC CGT TCC 48 Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 ATG GGT GAA GGT ACA ATA AAT GGC TTA CTG GAT GAA TTA TTA CAG ACA 96 Met Gly Glu Gly Thr He Asn Gly Leu Leu Asp Glu Leu Leu Gin Thr 20 25 30 AGG GTG CTG AAC AAG GAA GAG ATG GAG AAA GTA AAA CGT GAA AAT GCT 144 Arg Val Leu Asn Lys Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala 35 40 45 ACA GTT ATG GAT AAG ACC CGA GCT TTG ATT GAC TCC GTT ATT CCG AAA 192 Thr Val Met Asp Lys Thr Arg Ala Leu He Asp Ser Val He Pro Lys 50 55 60 GGG GCA CAG GCA TGC CAA ATT TGC ATC ACA TAC ATT TGT GAA GAA GAC 240 Gly Ala Gin Ala Cys Gin He Cys He Thr Tyr He Cys Glu Glu Asp 65 70 75 80 AGT TAC CTG GCA GGG ACG CTG GGA CTC TCA GCA GCT CCT CAG GCA GTG 288 Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Ala Pro Gin Ala Val 85 90 95 CAG GAC AAC CCA GCT ATG CCC ACA TCC TCA GGC TCA GAA GGG AAT GTC 336 Gin Asp Asn Pro Ala Met Pro Thr Ser Ser Gly Ser Glu Gly Asn Val 100 105 110 AAG CTT TGC TCC CTA GAA GAA GCT CAA AGG ATA TGG AAA CAA AAG TCG 384 Lys Leu Cys Ser Leu Glu Glu Ala Gin Arg He Trp Lys Gin Lys Ser 115 120 125 GCA GAG ATT TAT CCA ATA ATG GAC AAG TCA AGC CGC ACA CGT CTT GCT 432 Ala Glu He Tyr Pro He Met Asp Lys Ser Ser Arg Thr Arg Leu Ala 130 135 140 CTC ATT ATC TGC AAT GAA GAA TTT GAC AGT ATT CCT AGA AGA ACT GGA 480 Leu He He Cys Asn Glu Glu Phe Asp Ser He Pro Arg Arg Thr Gly 145 150 155 160 GCT GAG GTT GAC ATC ACA GGC ATG ACA ATG CTG CTA CAA AAT CTG GGG 528 Ala Glu Val Asp He Thr Gly Met Thr Met Leu Leu Gin Asn Leu Gly 165 170 175 TAC AGC GTA GAT GTG AAA AAA AAT CTC ACT GCT TCG GAC ATG ACT ACA 576 Tyr Ser Val Asp Val Lys Lys Asn Leu Thr Ala Ser Asp Met Thr Thr 180 185 190 GAG CTG GAG GCA TTT GCA CAC CGC CCA GAG CAC AAG ACC TCT GAC AGC 624 Glu Leu Glu Ala Phe Ala His Arg Pro Glu His Lys Thr Ser Asp Ser 195 200 205 ACG TTC CTG GTG TTC ATG TCT CAT GGT ATT CGG GAA GGC ATT TGT GGG 672 Thr Phe Leu Val Phe Met Ser His Gly He Arg Glu Gly He Cys Gly 210 215 220 AAG AAA CAC TCT GAG CAA GTC CCA GAT ATA CTA CAA CTC AAT GCA ATC 720 Lys Lys His Ser Glu Gin Val Pro Asp He Leu Gin Leu Asn Ala He 225 230 235 240 TTT AAC ATG TTG AAT ACC AAG AAC TGC CCA AGT TTG AAG GAC AAA CCG 768 Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser Leu Lys Asp Lys Pro 245 250 255 AAG GTG ATC ATC ATC CAG GCC TGC CGT GGT GAC AGC CCT GGT GTG GTG 816 Lys Val He He He Gin Ala Cys Arg Gly Asp Ser Pro Gly Val Val 260 265 270 TGG TTT AAA GAT TCA GTA GGA GTT TCT GGA AAC CTA TCT TTA CCA ACT 864 Trp Phe Lys Asp Ser Val Gly Val Ser Gly Asn Leu Ser Leu Pro Thr 275 280 285 ACA GAA GAG TTT GAG GAT GAT GCT ATT AAG AAA GCC CAC ATA GAG AAG 912 Thr Glu Glu Phe Glu Asp Asp Ala He Lys Lys Ala His He Glu Lys 290 295 300 GAT TTT ATC GCT TTC TGC TCT TCC ACA CCA GAT AAT GTT TCT TGG AGA 960 Asp Phe He Ala Phe Cys Ser Ser Thr Pro Asp Asn Val Ser Trp Arg 305 310 315 320 CAT CCC ACA ATG GGC TCT GTT TTT ATT GGA AGA CTC ATT GAA CAT ATG 1008 His Pro Thr Met Gly Ser Val Phe He Gly Arg Leu He Glu His Met 325 330 335 CAA GAA TAT GCC TGT TCC TGT GAT GTG GAG GAA ATT TTC CGC AAG GTT 1056 Gin Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu He Phe Arg Lys Val 340 345 350 CGA TTT TCA TTT GAG CAG CCA GAT GGT AGA GCG CAG ATG CCC ACC ACT 1104 Arg Phe Ser Phe Glu Gin Pro Asp Gly Arg Ala Gin Met Pro Thr Thr 355 360 365 GAA AGA GTG ACT TTG ACA AGA TGT TTC TAC CTC TTC CCA GGA CAT 1149 Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu Phe Pro Gly His 370 375 380 TAAAATAAGG AAACTGTATG AATGTCTGCG GGCAGG 1185 (2) INFORMATION FOR SEQ ID NO:4 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 383 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:4 : Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 Met Gly Glu Gly Thr He Asn Gly Leu Leu Asp Glu Leu Leu Gin Thr 20 25 30 Arg Val Leu Asn Lys Glu Glu Met Glu Lys Val Lys Arg Glu Asn Ala 35 40 45 Thr Val Met Asp Lys Thr Arg Ala Leu He Asp Ser Val He Pro Lys 50 55 60 Gly Ala Gin Ala Cys Gin He Cys He Thr Tyr He Cys Glu Glu Asp 65 70 75 80 Ser Tyr Leu Ala Gly Thr Leu Gly Leu Ser Ala Ala Pro Gin Ala Val 85 90 95 Gin Asp Asn Pro Ala Met Pro Thr Ser Ser Gly Ser Glu Gly Asn Val 100 105 110 Lys Leu Cys Ser Leu Glu Glu Ala Gin Arg He Trp Lys Gin Lys Ser 115 120 125 Ala Glu He Tyr Pro He Met Asp Lys Ser Ser Arg Thr Arg Leu Ala 130 135 140 Leu He He Cys Asn Glu Glu Phe Asp Ser He Pro Arg Arg Thr Gly 145 150 155 160 Ala Glu Val Asp He Thr Gly Met Thr Met Leu Leu Gin Asn Leu Gly 165 170 175 Tyr Ser Val Asp Val Lys Lys Asn Leu Thr Ala Ser Asp Met Thr Thr 180 185 190 Glu Leu Glu Ala Phe Ala His Arg Pro Glu His Lys Thr Ser Asp Ser 195 200 205 Thr Phe Leu Val Phe Met Ser His Gly He Arg Glu Gly He Cys Gly 210 215 220 Lys Lys His Ser Glu Gin Val Pro Asp He Leu Gin Leu Asn Ala He 225 230 235 240 Phe Asn Met Leu Asn Thr Lys Asn Cys Pro Ser Leu Lys Asp Lys Pro 245 250 255 Lys Val He He He Gin Ala Cys Arg Gly Asp Ser Pro Gly Val Val 260 265 270 Trp Phe Lys Asp Ser Val Gly Val Ser Gly Asn Leu Ser Leu Pro Thr 275 280 285 Thr Glu Glu Phe Glu Asp Asp Ala He Lys Lys Ala His He Glu Lys 290 295 300 Asp Phe He Ala Phe Cys Ser Ser Thr Pro Asp Asn Val Ser Trp Arg 305 310 315 320 His Pro Thr Met Gly Ser Val Phe He Gly Arg Leu He Glu His Met 325 330 335 Gin Glu Tyr Ala Cys Ser Cys Asp Val Glu Glu He Phe Arg Lys Val 340 345 350 Arg Phe Ser Phe Glu Gin Pro Asp Gly Arg Ala Gin Met Pro Thr Thr 355 360 365 Glu Arg Val Thr Leu Thr Arg Cys Phe Tyr Leu Phe Pro Gly His 370 375 380 (2) INFORMATION FOR SEQ ID NO:5 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 969 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..933 (xi) SEQUENCE DESCRIPTION: SEQ ID NO:5: ATG GCC GAC AAG GTC CTG AAG GAG AAG AGA AAG CTG TTT ATC CGT TCC 48 Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 ATG GGT GAA GCT CCT CAG GCA GTG CAG GAC AAC CCA GCT ATG CCC ACA 96 Met Gly Glu Ala Pro Gin Ala Val Gin Asp Asn Pro Ala Met Pro Thr - 36 - Gly Arg Ala Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys 290 295 300 TTC TAC CTC TTC CCA GGA CAT TAAAATAAGG AAACTGTATG AATGTCTGCG 963 Phe Tyr Leu Phe Pro Gly His 305 310 GGCAGG 969 (2) INFORMATION FOR SEQ ID NO: 6 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 311 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:6 : Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 Met Gly Glu Ala Pro Gin Ala Val Gin Asp Asn Pro Ala Met Pro Thr 20 25 30 Ser Ser Gly Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala 35 40 45 Gin Arg He Trp Lys Gin Lys Ser Ala Glu He Tyr Pro He Met Asp 50 55 60 Lys Ser Ser Arg Thr Arg Leu Ala Leu He He Cys Asn Glu Glu Phe 65 70 75 80 Asp Ser He Pro Arg Arg Thr Gly Ala Glu Val Asp He Thr Gly Met 85 90 95 Thr Met Leu Leu Gin Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn 100 105 110 Leu Thr Ala Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg 115 120 125 Pro Glu His Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His 130 135 140 Gly He Arg Glu Gly He Cys Gly Lys Lys His Ser Glu Gin Val Pro 145 150 155 160 Asp He Leu Gin Leu Asn Ala He Phe Asn Met Leu Asn Thr Lys Asn 165 170 175 Cys Pro Ser Leu Lys Asp Lys Pro Lys Val He He He Gin Ala Cys 180 185 190 Arg Gly Asp Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly Val 195 200 205 Ser Gly Asn Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala 210 215 220 He Lys Lys Ala His He Glu Lys Asp Phe He Ala Phe Cys Ser Ser 225 230 235 240 Thr Pro Asp Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe 245 250 255 - 35 - 20 25 30 TCC TCA GGC TCA GAA GGG AAT GTC AAG CTT TGC TCC CTA GAA GAA GCT 144 Ser Ser Gly Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala 35 40 45 CAA AGG ATA TGG AAA CAA AAG TCG GCA GAG ATT TAT CCA ATA ATG GAC 192 Gin Arg He Trp Lys Gin Lys Ser Ala Glu He Tyr Pro He Met Asp 50 55 60 AAG TCA AGC CGC ACA CGT CTT GCT CTC ATT ATC TGC AAT GAA GAA TTT 240 Lys Ser Ser Arg Thr Arg Leu Ala Leu He He Cys Asn Glu Glu Phe 65 70 75 80 GAC AGT ATT CCT AGA AGA ACT GGA GCT GAG GTT GAC ATC ACA GGC ATG 288 Asp Ser He Pro Arg Arg Thr Gly Ala Glu Val Asp He Thr Gly Met 85 90 95 ACA ATG CTG CTA CAA AAT CTG GGG TAC AGC GTA GAT GTG AAA AAA AAT 336 Thr Met Leu Leu Gin Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn 100 105 110 CTC ACT GCT TCG GAC ATG ACT ACA GAG CTG GAG GCA TTT GCA CAC CGC 384 Leu Thr Ala Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg 115 120 125 CCA GAG CAC AAG ACC TCT GAC AGC ACG TTC CTG GTG TTC ATG TCT CAT 432 Pro Glu His Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His 130 135 140 GGT ATT CGG GAA GGC ATT TGT GGG AAG AAA CAC TCT GAG CAA GTC CCA 480 Gly He Arg Glu Gly He Cys Gly Lys Lys His Ser Glu Gin Val Pro 145 150 155 160 GAT ATA CTA CAA CTC AAT GCA ATC TTT AAC ATG TTG AAT ACC AAG AAC 528 Asp He Leu Gin Leu Asn Ala He Phe Asn Met Leu Asn Thr Lys Asn 165 170 175 TGC CCA AGT TTG AAG GAC AAA CCG AAG GTG ATC ATC ATC CAG GCC TGC 576 Cys Pro Ser Leu Lys Asp Lys Pro Lys Val He He He Gin Ala Cys 180 185 190 CGT GGT GAC AGC CCT GGT GTG GTG TGG TTT AAA GAT TCA GTA GGA GTT 624 Arg Gly Asp Ser Pro Gly Val Val Trp Phe Lys Asp Ser Val Gly Val 195 200 205 TCT GGA AAC CTA TCT TTA CCA ACT ACA GAA GAG TTT GAG GAT GAT GCT 672 Ser Gly Asn Leu Ser Leu Pro Thr Thr Glu Glu Phe Glu Asp Asp Ala 210 215 220 ATT AAG AAA GCC CAC ATA GAG AAG GAT TTT ATC GCT TTC TGC TCT TCC 720 He Lys Lys Ala His He Glu Lys Asp Phe He Ala Phe Cys Ser Ser 225 230 235 240 ACA CCA GAT AAT GTT TCT TGG AGA CAT CCC ACA ATG GGC TCT GTT TTT 768 Thr Pro Asp Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe 245 250 255 ATT GGA AGA CTC ATT GAA CAT ATG CAA GAA TAT GCC TGT TCC TGT GAT 816 He Gly Arg Leu He Glu His Met Gin Glu Tyr Ala Cys Ser Cys Asp 260 265 270 GTG GAG GAA ATT TTC CGC AAG GTT CGA TTT TCA TTT GAG CAG CCA GAT 864 Val Glu Glu He Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro Asp 275 280 285 GGT AGA GCG CAG ATG CCC ACC ACT GAA AGA GTG ACT TTG ACA AGA TGT 912 He Gly Arg Leu He Glu His Met Gin Glu Tyr Ala Cys Ser Cys Asp 260 265 270 Val Glu Glu He Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro Asp 275 280 285 Gly Arg Ala Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys 290 295 300 Phe Tyr Leu Phe Pro Gly His 305 310 (2) INFORMATION FOR SEQ ID NO: 7: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 825 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..789 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7 : ATG GCC GAC AAG GTC CTG AAG GAG AAG AGA AAG CTG TTT ATC CGT TCC 48 Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 ATG GGT GAA GCT CCT CAG GCA GTG CAG GAC AAC CCA GCT ATG CCC ACA 96 Met Gly Glu Ala Pro Gin Ala Val Gin Asp Asn Pro Ala Met Pro Thr 20 25 30 TCC TCA GGC TCA GAA GGG AAT GTC AAG CTT TGC TCC CTA GAA GAA GCT 144 Ser Ser Gly Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala 35 40 45 CAA AGG ATA TGG AAA CAA AAG TCG GCA GAG ATT TAT CCA ATA ATG GAC 192 Gin Arg He Trp Lys Gin Lys Ser Ala Glu He Tyr Pro He Met Asp 50 55 60 AAG TCA AGC CGC ACA CGT CTT GCT CTC ATT ATC TGC AAT GAA GAA TTT 240 Lys Ser Ser Arg Thr Arg Leu Ala Leu He He Cys Asn Glu Glu Phe 65 70 75 80 GAC AGT ATT CCT AGA AGA ACT GGA GCT GAG GTT GAC ATC ACA GGC ATG 288 Asp Ser He Pro Arg Arg Thr Gly Ala Glu Val Asp He Thr Gly Met 85 90 95 ACA ATG CTG CTA CAA AAT CTG GGG TAC AGC GTA GAT GTG AAA AAA AAT 336 Thr Met Leu Leu Gin Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn 100 105 110 CTC ACT GCT TCG GAC ATG ACT ACA GAG CTG GAG GCA TTT GCA CAC CGC 384 Leu Thr Ala Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg 115 120 125 CCA GAG CAC AAG ACC TCT GAC AGC ACG TTC CTG GTG TTC ATG TCT CAT 432 Pro Glu His Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His 130 135 140 GGT ATT CGG GAA GGC ATT TGT GGG AAG AAA CAC TCT GAG CAA GTC CCA 480 Gly He Arg Glu Gly He Cys Gly Lys Lys His Ser Glu Gin Val Pro 145 150 155 160 GAT ATA CTA CAA CTC AAT GCA ATC TTT AAC ATG TTG AAT ACC AAG AAC 528 Asp He Leu Gin Leu Asn Ala He Phe Asn Met Leu Asn Thr Lys Asn 165 170 175 TGC CCA AGT TTG AAG GAC AAA CCG AAG GTG ATC ATC ATC CAG GCC TGC 576 Cys Pro Ser Leu Lys Asp Lys Pro Lys Val He He He Gin Ala Cys 180 185 190 CGT GGT GAT AAT GTT TCT TGG AGA CAT CCC ACA ATG GGC TCT GTT TTT 624 Arg Gly Asp Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe 195 200 205 ATT GGA AGA CTC ATT GAA CAT ATG CAA GAA TAT GCC TGT TCC TGT GAT 672 He Gly Arg Leu He Glu His Met Gin Glu Tyr Ala Cys Ser Cys Asp 210 215 220 GTG GAG GAA ATT TTC CGC AAG GTT CGA TTT TCA TTT GAG CAG CCA GAT 720 Val Glu Glu He Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro Asp 225 230 235 240 GGT AGA GCG CAG ATG CCC ACC ACT GAA AGA GTG ACT TTG ACA AGA TGT 768 Gly Arg Ala Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys 245 250 255 TTC TAC CTC TTC CCA GGA CAT TAAAATAAGG AAACTGTATG AATGTCTGCG 819 Phe Tyr Leu Phe Pro Gly His 260 GGCAGG 825 (2) INFORMATION FOR SEQ ID NO: 8 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 263 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:8 : Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 Met Gly Glu Ala Pro Gin Ala Val Gin Asp Asn Pro Ala Met Pro Thr 20 25 30 Ser Ser Gly Ser Glu Gly Asn Val Lys Leu Cys Ser Leu Glu Glu Ala 35 40 45 Gin Arg He Trp Lys Gin Lys Ser Ala Glu He Tyr Pro He Met Asp 50 55 60 Lys Ser Ser Arg Thr Arg Leu Ala Leu He He Cys Asn Glu Glu Phe 65 70 75 80 Asp Ser He Pro Arg Arg Thr Gly Ala Glu Val Asp He Thr Gly Met 85 90 95 Thr Met Leu Leu Gin Asn Leu Gly Tyr Ser Val Asp Val Lys Lys Asn 100 105 110 Leu Thr Ala Ser Asp Met Thr Thr Glu Leu Glu Ala Phe Ala His Arg 115 120 125 Pro Glu His Lys Thr Ser Asp Ser Thr Phe Leu Val Phe Met Ser His 130 135 140 Gly He Arg Glu Gly He Cys Gly Lys Lys His Ser Glu Gin Val Pro 145 150 155 160 Asp He Leu Gin Leu Asn Ala He Phe Asn Met Leu Asn Thr Lys Asn 165 170 175 Cys Pro Ser Leu Lys Asp Lys Pro Lys Val He He He Gin Ala Cys 180 185 190 Arg Gly Asp Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val Phe 195 200 205 He Gly Arg Leu He Glu His Met Gin Glu Tyr Ala Cys Ser Cys Asp 210 215 220 Val Glu Glu He Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro Asp 225 230 235 240 Gly Arg Ala Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg Cys 245 250 255 Phe Tyr Leu Phe Pro Gly His 260 (2) INFORMATION FOR SEQ ID NO:9 : (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 300 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (ix) FEATURE: (A) NAME/KEY: CDS (B) LOCATION: 1..264 (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 9 : ATG GCC GAC AAG GTC CTG AAG GAG AAG AGA AAG CTG TTT ATC CGT TCC 48 Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 ATG GGT GAA GAT AAT GTT TCT TGG AGA CAT CCC ACA ATG GGC TCT GTT 96 Met Gly Glu Asp Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val 20 25 30 TTT ATT GGA AGA CTC ATT GAA CAT ATG CAA GAA TAT GCC TGT TCC TGT 144 Phe He Gly Arg Leu He Glu His Met Gin Glu Tyr Ala Cys Ser Cys 35 40 45 GAT GTG GAG GAA ATT TTC CGC AAG GTT CGA TTT TCA TTT GAG CAG CCA 192 Asp Val Glu Glu He Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro 50 55 60 GAT GGT AGA GCG CAG ATG CCC ACC ACT GAA AGA GTG ACT TTG ACA AGA 240 Asp Gly Arg Ala Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg 65 70 75 80 TGT TTC TAC CTC TTC CCA GGA CAT TAAAATAAGG AAACTGTATG AATGTCTGCG 294 Cys Phe Tyr Leu Phe Pro Gly His 85 GGCAGG 300 (2) INFORMATION FOR SEQ ID NO:10: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 88 amino acids (B) TYPE: amino acid (D) TOPOLOGY: linear (ii) MOLECULE TYPE: protein (xi) SEQUENCE DESCRIPTION: SEQ ID NO:10: Met Ala Asp Lys Val Leu Lys Glu Lys Arg Lys Leu Phe He Arg Ser 1 5 10 15 Met Gly Glu Asp Asn Val Ser Trp Arg His Pro Thr Met Gly Ser Val 20 25 30 Phe He Gly Arg Leu He Glu His Met Gin Glu Tyr Ala Cys Ser Cys 35 40 45 Asp Val Glu Glu He Phe Arg Lys Val Arg Phe Ser Phe Glu Gin Pro 50 55 60 Asp Gly Arg Ala Gin Met Pro Thr Thr Glu Arg Val Thr Leu Thr Arg 65 70 75 80 Cys Phe Tyr Leu Phe Pro Gly His 85 (2) INFORMATION FOR SEQ ID NO:11: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 17 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 11: CAGAACGATC TCTTCAC 17 (2) INFORMATION FOR SEQ ID NO:12: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (li) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 12: ATGGCCGACA AGGTCCTG 18 (2) INFORMATION FOR SEQ ID NO:13: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 18 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY: linear (11) MOLECULE TYPE: cDNA (Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 13: CCTGCCCGCA GACATTCA 18 (2) INFORMATION FOR SEQ ID NO:14: (l) SEQUENCE CHARACTERISTICS: (A) LENGTH: 25 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ll) MOLECULE TYPE: cDNA (Xl) SEQUENCE DESCRIPTION: SEQ ID NO:14 : GGTTTCCAGA AACTCCTACT TAATC 25 (2) INFORMATION FOR SEQ ID NO:15: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 24 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: Single (D) TOPOLOGY: linear (ll) MOLECULE TYPE: cDNA (Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 15: ATGGCTATTA AGAAAGCCCA CATA 24 (2) INFORMATION FOR SEQ ID NO:16: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 30 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: single (D) TOPOLOGY- linear (ll) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:16: GGGATCCTGA ACCCAGCTAT GCCCACATCC 30 (2) INFORMATION FOR SEQ ID NO: 17: ( ) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY linear (ll) MOLECULE TYPE: cDNA (Xl) SEQUENCE DESCRIPTION: SEQ ID NO: 17: GCAGGTAAGG GTCATCTCTT GCAGCTCCT 29 (2) INFORMATION FOR SEQ ID NO:18: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 18: GAAGGTACAA TAAATCTCTT GCAGCTCCT 29 (2) INFORMATION FOR SEQ ID NO:19: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (Xi) SEQUENCE DESCRIPTION: SEQ ID NO: 19: GAAGGTACAA TAAATCTCTT GCAGCTCCT 29 (2) INFORMATION FOR SEQ ID NO:20: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:20: GGTGGTGAGT GCTGTTATCC ATAGATAAT 29 (2) INFORMATION FOR SEQ ID NO:21: (i) SEQUENCE CHARACTERISTICS: (A) LENGTH: 29 base pairs (B) TYPE: nucleic acid (C) STRANDEDNESS: double (D) TOPOLOGY: linear (ii) MOLECULE TYPE: cDNA (xi) SEQUENCE DESCRIPTION: SEQ ID NO:21: GAAGGTACAA TAAATTATCC ATAGATAAT 29

Claims: CLAIMS I. A substantially pure protein having the amino acid sequence of SEQ ID NO:4 , SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. 2. The protein of claim 1 wherein said protein has the amino acid sequence of SEQ ID NO:4. 3. The protein of claim 1 wherein said protein has the amino acid sequence of SEQ ID NO:6. 4. The protein of claim 1 wherein said protein has the amino acid sequence of SEQ ID NO:8. 5. A pharmaceutical composition comprising the protein of claim 4 and a pharmaceutically acceptable carrier. 6. The protein of claim 1 wherein said protein has the amino acid sequence of SEQ ID NO: 10. 7. A pharmaceutical composition comprising the protein of claim 6 and a pharmaceutically acceptable carrier. 8. An isolated nucleic acid molecule consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO: 7 or SEQ ID NO: 9 or a fragment thereof having at least 10 nucleotides. 9. The nucleic acid molecule of claim 8 consisting of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO: 7 or SEQ ID NO: 9. 10. A recombinant expression vector comprising a nucleic acid sequence that encodes the protein of claim 1. II. A host cell comprising the recombinant expression vector of claim 10. 12. A recombinant expression vector comprising the nucleic acid molecule of claim 9. 13. A host cell comprising the recombinant expression vector of claim 12. 14. The nucleic acid molecule of claim 8 consisting of a fragment of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO: 9 having at least 10 nucleotides. 15. The nucleic acid molecule of claim 8 consisting of a fragment of SEQ ID NO: 3 , SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9 having 12-150 nucleotides. 16. The nucleic acid molecule of claim 8 consisting of a fragment of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO:7 or SEQ ID NO: 9 having 15-50 nucleotides. 17. The nucleic acid molecule of claim 8 consisting of a fragment of SEQ ID NO:3, SEQ ID NO:5, SEQ ID NO:7 or SEQ ID NO: having 18-30 nucleotides. 18. The nucleic acid molecule of claim 8 consisting of a fragment of SEQ ID NO:3 , SEQ ID NO: 5 , SEQ ID NO:7 or SEQ ID NO: 9 having 24 nucleotides. 19. An oligonucleotide molecule comprising a nucleotide sequence complimentary to a nucleotide sequence of at least 10 nucleotides of SEQ ID NO:3 , SEQ ID NO: 5, SEQ ID NO:7 or SEQ ID NO: 9. 20. The oligonucleotide molecule of claim 19 consisting of a nucleotide sequence complimentary to a nucleotide sequence of at least 10-150 nucleotides of SEQ ID NO: 3 , SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. 21. The oligonucleotide molecule of claim 19 consisting of a nucleotide sequence complimentary to a nucleotide sequence of at least 18-28 nucleotides of SEQ ID NO: 3, SEQ ID NO: 5, SEQ ID NO: 7 or SEQ ID NO: 9. 22. An isolated antibody which binds to an epitope on SEQ ID N0:4, SEQ ID NO: 6, SEQ ID NO: 8 or SEQ ID NO: 10. 23. The antibody of claim 22 which binds to an epitope on SEQ ID NO:4. 24. The antibody of claim 22 which binds to an epitope on SEQ ID NO:6. 25. The antibody of claim 22 which binds to an epitope on SEQ ID NO:8. 26. The antibody of claim 22 which binds to an epitope on SEQ ID NO: 10. 27. The antibody of claim 22 wherein said antibody is a monoclonal antibody. 28. A method of identifying inhibitors of ICE isoforms comprising the steps of : performing a control assay by contacting an ICE isoform with proIL-13 in the absence of a test compound under conditions in which said ICE isoform processes said proIL-1/3, performing a test assay by contacting an ICE isoform with proIL-1/3 in the presence of a test compound under conditions in which said ICE isoform processes said proIL-1 / 3 in the absence of said test compound, determining whether said test compound inhibits said ICE iosform activity by comparing activity of said ICE isoform in said control assay and said test assay by detecting whether said ICE isoform is active and processes - 46 - said proIL-1/3 in said control assay and whether said ICE isoform is inactive and does not process said proIL-1/3 in said test assay.

Inventors: ALNEMRI EMAD S, FERNANDEZ-ALNEMRI TERESA, LITWACK GERALD, ALNEMRI, EMAD, S., FERNANDEZ-ALNEMRI, TERESA, LITWACK, GERALD
Applicants: UNIV JEFFERSON, THOMAS JEFFERSON UNIVERSITY
Application year: 1996
Main classification: A61K38
IPC codes: A01K67, A61K38, A61K39, A61K48, A61P3, A61P29, A61P37, C12N1, C12N9, C12N15, C12R1, G01N33